SKU: DJ-CAGRISEMA-5MG
4th of July Sale price — extra discount by quantity on this line
| Quantity | Price / Unit | Discount |
|---|---|---|
| 5–9 | $47.49 | 5% |
| 10–15 | $44.99 | 10% |
| 16–20 | $42.49 | 15% |
| 21+ | $39.99 | 20% |
Research use only — not for human or veterinary consumption.
Research Grade Peptide Blend
Advanced Dr. Jays Cagri + Dr. Jay's Sema research blend supplied for laboratory and analytical applications. Lyophilized, sealed, and prepared per research-product handling standards.
Product Highlights
DRJAYS Cagri-Sema™ is supplied as a lyophilized, sealed research peptide blend — prepared around the practical needs of analytical laboratories.
Freeze-dried Dr. Jays Cagri + Dr. Jay's Sema blend supplied in a sterile sealed research vial.
Single 5mg lyophilized research vial, ready for documented laboratory workflows.
Sealed and inspected per research-product packaging conventions.
Backed by Dr. Jay's Knowledge Hub and Peptide University™ reference content.
Product Overview
Cagri-Sema is a co-formulated research peptide blend of Dr. Jays Cagri and Dr. Jay's Sema, widely referenced in laboratory investigation of amylin and GLP-1 receptor signaling and related analytical study.
Research Visualization
Stage 1
Research Compound
Stage 2
Laboratory Preparation
Stage 3
Analytical Evaluation
Stage 4
Data Collection
Stage 5
Research Review
Specifications
| Product Name | DRJAYS Cagri-Sema™ |
|---|---|
| Composition | Dr. Jays Cagri + Dr. Jay's Sema |
| Format | Lyophilized Powder |
| Appearance | White to Off-White |
| Strength | 5MG per Vial |
| Container | Sterile Research Vial |
| Storage | Refrigerated (2–8°C) |
| Category | Research Peptide Blend |
| Intended Use | Laboratory Research |
Quality Standards
Step 1
Quality Review
Step 2
Packaging Verification
Step 3
Batch Documentation
Step 4
Storage Preparation
Step 5
Shipment Processing
Scientific Research
Common categories where lyophilized research peptide blends like DRJAYS Cagri-Sema™ support analytical and procedural laboratory work.
Reference input for structural analysis and peptide property investigation.
Assessment of peptide integrity under documented laboratory storage conditions.
Laboratory examination using identity, purity, and stability instrumentation.
Supports protocol development, batch tracking, and laboratory data collection.
Scientific investigation of peptide characteristics across controlled studies.
Use within controlled research and analytical environments.
Why Dr. Jay's
Curated catalog of research peptides for analytical and educational use.
Knowledge Hub, encyclopedia entries, and structured Peptide University™ modules.
Complimentary access to the central educational reference library.
Sealed research vials and inspected outer packaging on every order.
Documented preparation, packaging verification, and batch logging sequence.
Knowledgeable customer support for order, shipment, and resource inquiries.
Interactive Knowledge Hub
Explore the surrounding library of educational reference material curated by Dr. Jay's.
Navigate the research compound catalog by category, target, and format.
Open resource →Structured educational modules covering peptide research fundamentals.
Open resource →Central educational reference library curated by Dr. Jay's.
Open resource →In-depth research guides and compound encyclopedia entries.
Open resource →How-to-mix reference for lyophilized research peptide reconstitution.
Open resource →Educational reference content covering veterinary research topics.
Open resource →Trust & Authority
Keep exploring
Dive deeper into the surrounding educational ecosystem from Dr. Jay's — finders, structured modules, and reference guides.
Researchers looking for semaglutide research blend for sale can buy semaglutide research blends from Dr Jays Peptides with confidence: every Cagri-Sema (cagrilintide + semaglutide research blend) lyophilized research peptide blend we supply is sourced direct from our Swiss pharmaceutical-grade manufacturer — the same pharmaceutical-grade contract manufacturer trusted across the global research peptide industry — and shipped from our domestic Florida fulfillment center. Cagri-Sema (cagrilintide + semaglutide research blend) is supplied here exclusively for laboratory and analytical research use; it is not a medicine, supplement, or product for human or veterinary consumption.
Each Cagri-Sema (cagrilintide + semaglutide research blend) order ships with 5mg sealed research vial, manufactured under strict quality procedures, sealed for integrity, and packaged for protected research-grade transit. Researchers commonly evaluate cagrilintide + semaglutide reference material for analytical, formulation, and mechanistic studies.
Cagri-Sema (cagrilintide + semaglutide research blend) supplied by Dr Jays Peptides is sourced direct from our Swiss pharmaceutical-grade manufacturer, with batch documentation retained on file. This is the same provenance qualified laboratories look for when sourcing reference material — transparent origin, traceable batch records, and independently verifiable identity rather than anonymous bulk powder.
Orders for semaglutide research blend for sale dispatch from our Florida fulfillment center with tracking provided. Domestic shipping shortens transit, reduces handling steps, and keeps Cagri-Sema (cagrilintide + semaglutide research blend)research material in a controlled cold-chain workflow until it reaches your laboratory.
All Cagri-Sema (cagrilintide + semaglutide research blend) material from Dr Jays Peptides is sold strictly for in-vitro and pre-clinical laboratory research. We do not provide dosing protocols, therapeutic guidance, or any instruction implying human or veterinary use. Research design and handling are the responsibility of the qualified investigator.
Background reading: Cagri-Sema (cagrilintide + semaglutide research blend) encyclopedia entry — mechanism context and references for the qualified researcher.
Cagri-Sema is a research-peptide combination that pairs two long-acting peptides — cagrilintide (a lipidated amylin analog) and semaglutide (a lipidated GLP-1 receptor agonist) — in a single lyophilized vial for laboratory research on the complementary pharmacology of the two compounds. The combination concept emerged from the recognition that amylin signaling and GLP-1 receptor signaling are mechanistically distinct but functionally complementary, and that simultaneous engagement of both receptor systems produces integrated effects that have been the subject of substantial preclinical and clinical research over the past several years.
The conceptual story behind Cagri-Sema is the convergence of two threads of contemporary peptide-engineering and metabolic-pharmacology research. First is the long-acting lipidated GLP-1 receptor agonist line — anchored by liraglutide (approved 2009) and semaglutide (approved 2017) at Novo Nordisk — that has produced one of the most important contemporary pharmacology stories in the metabolic-research space. Second is the amylin / calcitonin-receptor pharmacology that began with pramlintide (approved 2005) and that has more recently produced the long-acting lipidated amylin analog cagrilintide. The CagriSema research program at Novo Nordisk has characterized the combination of these two compounds in extensive preclinical and clinical research as a representative example of complementary multi-receptor combination pharmacology.
This page is an educational reference for readers who want to understand what the Cagri-Sema combination actually is, how the two component compounds work individually and in combination, what the published literature describes about the combination pharmacology, and where the combination sits in the broader metabolic-research landscape. It is not a medical-use guide, does not describe any therapy or personal-application protocol, and makes no claims about effects in people who acquire the compound for research purposes. Cagri-Sema supplied as a research peptide in this context is intended for laboratory and analytical work only.
Cagri-Sema is a lyophilized combination of cagrilintide and semaglutide in a single vial, supplied for laboratory research on the combination pharmacology of the two compounds. Each component is a long-acting lipidated peptide with multi-day elimination half-life suitable for once-weekly dosing in research and clinical contexts; the combination contains both compounds together for studies that examine the integrated effect profile of simultaneous amylin and GLP-1 receptor engagement.
Cagrilintide is a 37-amino-acid amylin analog built on the pramlintide-style proline-substituted scaffold (with proline residues at positions 25, 28, and 29 that prevent the aggregation behavior of the native human amylin sequence) and modified with a fatty-acid side chain attached through a glutamic-acid spacer at one of the lysine residues. The fatty-acid side chain produces albumin-binding pharmacokinetics that extend the elimination half-life into the multi-day range. The compound is a class B GPCR agonist at the amylin / calcitonin / RAMP receptor architecture, engaging all three amylin-receptor subtypes (AMY1, AMY2, AMY3) and retaining activity at the calcitonin receptor itself.
Semaglutide is a 31-amino-acid GLP-1 receptor agonist built on the natural GLP-1(7-37) scaffold with two specific modifications: a substitution of alpha-aminoisobutyric acid (Aib) for the alanine at position 8 that prevents DPP-4 protease cleavage, and a fatty-acid side chain (a C18 di-acid attached through a glutamic-acid-and-OEG spacer) at lysine 26 that produces albumin-binding pharmacokinetics. Semaglutide is a class B GPCR agonist at the GLP-1 receptor, signaling through the canonical incretin-receptor pathway that produces effects on insulin secretion, glucagon secretion, satiety signaling, and gastric-emptying regulation.
The two compounds are mechanistically complementary rather than redundant. Cagrilintide acts through the amylin / CT / RAMP receptor system; semaglutide acts through the GLP-1 receptor. The receptor systems are distinct, the signaling cascades are partially overlapping (both involve Gs / cyclic AMP / PKA signaling at the receptor level) but engage different downstream substrates and different tissue-specific responses. The integrated effect profile of the combination has been characterized in extensive research as exceeding the effect of either compound alone in several relevant endpoints.
It is worth being specific about what Cagri-Sema is not. It is not a single fusion peptide combining the two pharmacologies in one molecule (that would be a different research direction, exemplified by the tirzepatide GIP-and-GLP-1 dual agonist and by various other multi-receptor agonist research programs). It is also not a fixed-ratio formulation in the regulatory sense — the research-peptide combination supply contains the two compounds together for laboratory research on the combination pharmacology, with the relative amounts and the reconstitution and dosing decisions made in the laboratory-research context.
The history of the Cagri-Sema combination sits inside the broader contemporary history of long-acting peptide engineering at Novo Nordisk and the emergence of multi-receptor combination pharmacology in the metabolic-research space.
The long-acting lipidated GLP-1 receptor agonist line at Novo Nordisk began with liraglutide, approved by the U.S. FDA in 2010 (originally approved by the European Medicines Agency in 2009). Liraglutide demonstrated that the lipidation strategy — attaching a fatty-acid side chain through a glutamic-acid spacer to produce albumin-binding pharmacokinetics — could extend the elimination half-life of a GLP-1 receptor agonist from minutes (the natural GLP-1) to a day or more, enabling once-daily dosing. Semaglutide, approved 2017 (subcutaneous formulation) and 2019 (oral formulation, with an additional absorption-enhancer technology), extended the half-life further with a different fatty-acid-side-chain design and a more potent receptor-engagement profile, enabling once-weekly dosing.
The amylin-receptor line at Novo Nordisk produced cagrilintide as the long-acting lipidated descendant of the pramlintide-style amylin scaffold. The cagrilintide development program in the 2010s applied the same general lipidation engineering platform that had produced liraglutide and semaglutide to the amylin scaffold, producing a long-acting amylin analog with the same once-weekly-dosing pharmacokinetic profile as the long-acting GLP-1 receptor agonists.
The conceptual rationale for combining cagrilintide and semaglutide emerged from the recognition that the amylin and GLP-1 receptor signaling systems are mechanistically distinct but functionally complementary. Both systems are involved in satiety signaling and gastrointestinal regulation, but they act through different receptors with different downstream signaling and different tissue-specific response patterns. The hypothesis was that simultaneous engagement of both systems would produce integrated effects exceeding the effects of either system alone.
The CagriSema clinical-research program at Novo Nordisk has characterized the combination in extensive Phase 1, 2, and 3 trials over the past several years, addressing the pharmacokinetics of the combination (the two compounds have similar multi-day half-lives that allow co-administration on a once-weekly schedule), the pharmacodynamics of the combination on a range of metabolic and satiety-related endpoints, and the safety and tolerability profile of the combination relative to the individual compounds. The program is among the most prominent contemporary examples of multi-receptor combination pharmacology in the metabolic-research space.
Important milestones include the 2009-2010 approval of liraglutide, the 2017 approval of subcutaneous semaglutide, the 2010s cagrilintide development at Novo Nordisk, and the 2020s CagriSema combination characterization in extensive preclinical and clinical research.
The science of the Cagri-Sema combination is anchored in three connected areas: the individual receptor pharmacology of the amylin and GLP-1 receptor systems, the integrated pharmacology of simultaneous engagement of both systems, and the pharmacokinetic-pharmacodynamic relationship of the combination in chronic-dosing research contexts.
Cagrilintide is an agonist at the amylin receptors, which are heterodimers built from the calcitonin receptor (CT receptor, a class B G-protein-coupled receptor) in combination with one of three receptor-activity-modifying proteins (RAMPs). The three combinations generate the three amylin-receptor subtypes: AMY1 (CT/RAMP1), AMY2 (CT/RAMP2), and AMY3 (CT/RAMP3). The integrated tissue-level effects of amylin signaling include satiety signaling at brainstem amylin-receptor sites (particularly the area postrema circumventricular region), slowing of gastric emptying at gastrointestinal sites, and modulation of glucagon secretion at pancreatic alpha-cell sites.
Semaglutide is an agonist at the GLP-1 receptor, a class B G-protein-coupled receptor expressed prominently on pancreatic beta cells, on pancreatic alpha cells, in the central nervous system, and on various peripheral tissue sites. The integrated tissue-level effects of GLP-1 receptor signaling include glucose-dependent stimulation of insulin secretion from pancreatic beta cells, suppression of glucagon secretion from pancreatic alpha cells, satiety signaling at central GLP-1-receptor-expressing neuronal populations, and slowing of gastric emptying. The downstream signaling at the GLP-1 receptor proceeds through Gs / cyclic AMP / PKA cascades with additional involvement of EPAC, ERK, and other secondary pathways.
The pharmacological rationale for the Cagri-Sema combination is the complementary integrated pharmacology of the two receptor systems. The amylin and GLP-1 systems both contribute to satiety signaling and gastrointestinal regulation, but they act through distinct receptors with distinct downstream signaling and distinct tissue-specific response patterns. The integrated effect profile of simultaneous engagement has been characterized in research as producing effects on satiety-related and metabolic endpoints that exceed those of either component compound alone. The combination is sometimes described as engaging the "amylin pillar" and the "incretin pillar" of metabolic signaling simultaneously.
A practical requirement for a combination of long-acting peptides is pharmacokinetic compatibility — the elimination half-lives of the component compounds need to be similar enough to allow co-administration on a single dosing schedule. Cagrilintide and semaglutide both have multi-day elimination half-lives supporting once-weekly administration, produced by the analogous lipidation strategies that generate albumin-binding pharmacokinetics for both compounds. The pharmacokinetic compatibility of the two compounds is one of the design features that makes the combination practical in research and clinical contexts.
Cagrilintide and semaglutide are highly selective for their respective receptor systems. Cagrilintide does not engage the GLP-1 receptor at concentrations relevant in research and clinical contexts, and semaglutide does not engage the amylin / CT / RAMP receptors. The combination therefore produces parallel engagement of two distinct receptor systems rather than cross-engagement of either compound at the other's target receptor. The combination effects are integrated at the cellular and tissue level downstream of the parallel receptor activations rather than at the receptor-binding level.
Structurally, the Cagri-Sema combination contains two distinct long-acting lipidated peptides with distinct sequence and modification profiles.
Cagrilintide is a 37-amino-acid linear peptide with a disulfide-bridged N-terminal loop (between cysteines at positions 2 and 7) and a C-terminal amide. The amino-acid backbone retains the pramlintide-style proline substitutions at positions 25, 28, and 29 that prevent the aggregation behavior of the native human amylin sequence. A fatty-acid side chain (typically a C18 di-acid attached through a glutamic-acid spacer) is conjugated to a lysine residue, producing the albumin-binding pharmacokinetics that extend the elimination half-life into the multi-day range. The molecular mass of cagrilintide is approximately 4250 daltons.
Semaglutide is a 31-amino-acid linear peptide built on the GLP-1(7-37) scaffold with the alpha-aminoisobutyric acid (Aib) substitution at position 8 (preventing DPP-4 cleavage that would otherwise rapidly inactivate the peptide) and the fatty-acid side chain (a C18 di-acid attached through a glutamic-acid-and-OEG spacer) at lysine 26 (producing the albumin-binding pharmacokinetics). The molecular mass of semaglutide is approximately 4114 daltons.
The combination vial contains both compounds in a single lyophilized cake, with the relative amounts determined by the specific product configuration. After reconstitution in sterile water or bacteriostatic water, the combination produces a solution containing both peptides for laboratory research on the combination pharmacology. Both compounds retain their individual structural and pharmacological identities in the combination; the combination does not produce any covalent or non-covalent interaction between the two compounds that would alter their individual properties.
Both compounds share the same general engineering principle — a long-acting lipidated peptide with albumin-binding pharmacokinetics produced by a fatty-acid side chain attached through a glutamic-acid-containing spacer — although the specific scaffold and the specific spacer chemistry differ between the two. The shared engineering principle is reflective of the Novo Nordisk lipidation technology platform that has produced multiple long-acting peptide therapeutics over the past two decades.
Cagri-Sema is studied in laboratory contexts that span multi-receptor combination pharmacology, amylin and GLP-1 receptor signaling integration, satiety-signaling and energy-balance research, and broader long-acting peptide combination engineering.
In multi-receptor combination pharmacology, Cagri-Sema serves as a representative example of complementary combination engagement of two distinct receptor systems. The combination is used in research on the principles of complementary receptor engagement, on the pharmacological characterization of integrated effect profiles relative to component effects, on the comparative pharmacology of combination dosing versus single-compound dosing, and on the broader principles of multi-receptor combination strategies in peptide pharmacology.
In amylin and GLP-1 receptor signaling integration research, Cagri-Sema is studied in research on the integrated downstream signaling at the cellular and tissue level when both receptor systems are engaged simultaneously, on the integration of satiety signaling from the two systems at central nervous system sites, on the integration of gastrointestinal effects from the two systems at the gut level, and on the integration of pancreatic effects (insulin, glucagon, beta-cell function) at the islet level.
In satiety-signaling and energy-balance research, Cagri-Sema appears in research on the chronic effects of sustained engagement of both signaling systems on energy-balance endpoints, on the pharmacology of satiety-related signaling in central nervous system contexts, and on the integration of metabolic signaling in chronic-dosing research contexts.
In broader long-acting peptide combination engineering research, Cagri-Sema serves as a worked example of how two long-acting peptides with pharmacokinetically compatible profiles can be combined in a single research-peptide vial for research on combination pharmacology. The combination is used in methodology-research contexts on combination-peptide formulation, on stability characterization of combination preparations, on analytical methodology for combination-peptide characterization (HPLC and mass spectrometry of combination preparations), and on the broader principles of combination-peptide research.
Across all of these contexts, the research applications in the research-peptide supply context are laboratory and analytical in nature. The compound's status as an investigational combination in clinical research is a separate channel from the research-peptide supply for laboratory work.
Cagri-Sema sits within the broader contemporary landscape of multi-receptor combination and dual-agonist research compounds, with related but distinguishable comparators across the multi-compound-combination, dual-agonist, and single-receptor categories.
| Compound | Classification | Distinguishing feature |
|---|---|---|
| Cagrilintide (standalone) | Long-acting amylin analog | One of the two component compounds of Cagri-Sema; engages only the amylin / CT / RAMP receptors; the amylin-pillar component of the combination pharmacology. |
| Semaglutide (standalone) | Long-acting GLP-1 receptor agonist | The other component compound of Cagri-Sema; engages only the GLP-1 receptor; the incretin-pillar component of the combination pharmacology. |
| Tirzepatide | Single-molecule GIP / GLP-1 dual receptor agonist | Different combination strategy — a single peptide molecule engineered to engage both GIP and GLP-1 receptors, rather than two compounds engaging two receptors. Different pharmacological pillars (GIP and GLP-1 rather than amylin and GLP-1). |
| Retatrutide | Single-molecule GIP / GLP-1 / glucagon triple receptor agonist | Further extension of the single-molecule multi-receptor approach; engages three different receptor systems in one peptide molecule. |
| Pramlintide + GLP-1 analogs | Short-acting combination research direction | Historical research direction combining the short-acting amylin analog pramlintide with various GLP-1 receptor agonists; the conceptual ancestor of the long-acting Cagri-Sema combination. |
Cagri-Sema is a research-peptide combination containing two long-acting peptides: cagrilintide (a lipidated amylin analog acting at the amylin / calcitonin / RAMP receptor system) and semaglutide (a lipidated GLP-1 receptor agonist). The combination is supplied for laboratory research on the integrated pharmacology of simultaneous engagement of the amylin and GLP-1 receptor systems. The two compounds are mechanistically complementary rather than redundant.
The combination engages two distinct receptor systems — the amylin / calcitonin / RAMP receptors via cagrilintide and the GLP-1 receptor via semaglutide — in parallel. The two systems both contribute to satiety signaling, gastrointestinal regulation, and metabolic signaling, but they act through different receptors with different downstream signaling and different tissue-specific response patterns. The integrated effect profile of simultaneous engagement has been characterized in research as producing effects on satiety-related and metabolic endpoints that exceed the effects of either component compound alone.
Different combination strategy. Cagri-Sema is two distinct peptide compounds (cagrilintide + semaglutide) co-administered to engage two distinct receptor systems (amylin/CT/RAMP and GLP-1) in parallel. Tirzepatide is a single peptide molecule engineered to engage two different receptor systems (GIP and GLP-1) within one molecule. The two approaches address conceptually different combination strategies — multi-compound combination versus single-molecule dual-agonism — and they engage different pharmacological pillars (amylin and GLP-1 for Cagri-Sema; GIP and GLP-1 for tirzepatide).
Cagri-Sema is the research-and-clinical-program name for the combination of cagrilintide and semaglutide, both developed at Novo Nordisk. The CagriSema clinical-research program at Novo Nordisk has characterized the combination in extensive preclinical and clinical research over the past several years. The research-peptide supply of the combination for laboratory work is a separate channel from the Novo Nordisk clinical-research program.
In the research-peptide combination supply, the two compounds (cagrilintide and semaglutide) are present together in a single lyophilized cake in the supplied vial. Reconstitution with sterile water or bacteriostatic water produces a solution containing both peptides. The relative amounts of the two compounds in the vial are determined by the specific product configuration. The combination is not a single fusion molecule — the two compounds retain their individual structural and pharmacological identities throughout.
Yes. Both compounds are long-acting lipidated peptides with multi-day elimination half-lives suitable for once-weekly dosing in research and clinical contexts. Cagrilintide's half-life is in the multi-day range produced by the lipidation-driven albumin binding; semaglutide's half-life is similarly in the multi-day range. The compatibility of the two pharmacokinetic profiles is one of the design features that makes once-weekly co-administration of the combination practical, and it is part of why the long-acting Cagri-Sema combination is a more practical research direction than earlier combination approaches that involved short-acting amylin analogs.
Cagrilintide does not engage the GLP-1 receptor at concentrations relevant in research and clinical contexts, and semaglutide does not engage the amylin / calcitonin / RAMP receptors. The two compounds are highly selective for their respective receptor systems. The combination produces parallel engagement of two distinct receptor systems rather than cross-engagement of either compound at the other's target receptor. The combination effects are integrated at the cellular and tissue level downstream of the parallel receptor activations rather than at the receptor-binding level.
The amylin receptors are heterodimers built from the calcitonin receptor (CT receptor, a class B G-protein-coupled receptor) in combination with one of three receptor-activity-modifying proteins (RAMP1, RAMP2, or RAMP3). The three combinations generate the three amylin-receptor subtypes (AMY1, AMY2, AMY3). Cagrilintide engages all three AMY subtypes and retains activity at the CT receptor itself. The amylin signaling system is involved in satiety signaling at brainstem sites, slowing of gastric emptying at gastrointestinal sites, and modulation of glucagon secretion at pancreatic alpha-cell sites.
The GLP-1 receptor is a class B G-protein-coupled receptor expressed prominently on pancreatic beta cells, on pancreatic alpha cells, in the central nervous system, and on various peripheral tissue sites. The receptor responds to the natural GLP-1 (glucagon-like peptide-1, secreted from intestinal L cells in response to nutrient stimuli) and to synthetic GLP-1 receptor agonists including semaglutide. The integrated effects of GLP-1 receptor signaling include glucose-dependent insulin secretion, glucagon suppression, satiety signaling, and slowing of gastric emptying.
The CagriSema combination is an investigational combination that has been the subject of extensive preclinical and clinical research at Novo Nordisk. As of the most recent updates, the combination is in advanced clinical development. The research-peptide supply of the combination for laboratory work is a separate channel from the Novo Nordisk clinical-research program and from any approved-product channels.
The native human amylin sequence has a region of three consecutive amino acids that promote beta-sheet self-aggregation and amyloid-fibril formation, making the native sequence impractical as a pharmaceutical because it would precipitate out of solution. The pramlintide-style proline substitutions at positions 25, 28, and 29 (based on the corresponding residues in rat amylin, which does not aggregate) prevent this aggregation. Cagrilintide inherits these proline substitutions, which is why the long-acting amylin component of the Cagri-Sema combination is stable and storable in solution.
Alpha-aminoisobutyric acid (Aib) is a non-proteinogenic amino acid used as a substitute for the alanine at position 8 of the natural GLP-1 sequence. The substitution prevents cleavage by the protease DPP-4 (dipeptidyl peptidase-4) that would otherwise rapidly inactivate the natural GLP-1 by removing the N-terminal dipeptide. The Aib substitution is one of the two key modifications in semaglutide (the other being the fatty-acid side chain at lysine 26) that together produce the long-acting pharmacology.
After reconstitution in sterile water or bacteriostatic water, the combination is typically stored refrigerated and used within several weeks. Both component compounds have good chemical stability in the reconstituted state — cagrilintide due to the pramlintide-style proline-substituted scaffold, and semaglutide due to the Aib substitution and the lipidation modifications. Standard research-laboratory storage and handling practices apply. The lyophilized vial stored sealed at -20 °C or below away from light is generally considered stable for extended periods.
The combination contains two distinct compounds with distinct molecular masses: cagrilintide at approximately 4250 daltons and semaglutide at approximately 4114 daltons. The combination is not a single fusion molecule; the two compounds are present together in the lyophilized vial as separate molecular entities. The relative amounts of the two compounds in the combination vial are determined by the specific product configuration and are reported on the Certificate of Analysis.
Incretin is the broad term for gut-derived peptide hormones that stimulate insulin secretion from pancreatic beta cells in response to nutrient stimuli. The two principal incretin hormones are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 receptor agonists like semaglutide are sometimes described as 'incretin mimetics' because they mimic the action of the natural GLP-1 incretin hormone. The incretin-mimetic pharmacology of semaglutide is one of the two pharmacological pillars of the Cagri-Sema combination, complementary to the amylin pharmacology of cagrilintide.
Pharmacologically, the combination engages the same two receptor systems whether the compounds are supplied together in a combination vial or separately as individual compounds and co-administered. The combination-vial format is a practical convenience for laboratory research on the combination pharmacology, ensuring that the two compounds are present together in the proportion intended for the combination research and reducing the steps required for combination-research preparation. The pharmacological characterization of the combination effects is not different between the two supply formats.
Comprehensive safety characterization of the CagriSema combination is ongoing as part of the clinical-research program at Novo Nordisk. The combination's safety profile in research and clinical contexts continues to be characterized in the various studies addressing the combination pharmacology. The research-peptide supply of the combination for laboratory work is a separate channel from the clinical-research channel; the comprehensive safety characterization is applicable to the clinical-research context rather than to laboratory research-peptide use. Educational discussion should remain within the laboratory-research and clinical-research framings appropriate to the actual use channels.
Cagri-Sema is a research-peptide combination containing two long-acting peptides — cagrilintide (a lipidated amylin analog) and semaglutide (a lipidated GLP-1 receptor agonist) — supplied for laboratory research on the combination pharmacology of the amylin and GLP-1 receptor systems. The combination concept emerged from the recognition that amylin signaling and GLP-1 receptor signaling are mechanistically distinct but functionally complementary, and that simultaneous engagement of both receptor systems produces integrated effects that exceed those of either system alone.
The two component compounds are both long-acting lipidated peptides developed at Novo Nordisk using the same general engineering platform — a fatty-acid side chain attached through a glutamic-acid spacer to produce albumin-binding pharmacokinetics with multi-day elimination half-life. Cagrilintide is a 37-amino-acid amylin analog built on the pramlintide-style proline-substituted scaffold; semaglutide is a 31-amino-acid GLP-1 receptor agonist built on the GLP-1(7-37) scaffold with the Aib substitution at position 8. The pharmacokinetic compatibility of the two compounds allows once-weekly co-administration.
The two compounds are highly selective for their respective receptor systems — cagrilintide for the amylin / CT / RAMP receptors and semaglutide for the GLP-1 receptor — with no cross-engagement at the other compound's target receptor. The combination effects are integrated at the cellular and tissue level downstream of the parallel receptor activations.
The CagriSema clinical-research program at Novo Nordisk has characterized the combination in extensive preclinical and clinical research over the past several years, addressing the combination pharmacokinetics, the integrated pharmacodynamics across a range of metabolic and satiety-related endpoints, and the safety and tolerability profile. The combination is among the most prominent contemporary examples of multi-receptor combination pharmacology in the metabolic-research space.
For students, researchers, and curious readers approaching Cagri-Sema for the first time, the most accurate framing is of a thoughtfully designed multi-receptor combination research peptide that engages two distinct but complementary receptor systems in parallel, distinguished from single-molecule multi-receptor agonists (such as tirzepatide or retatrutide) by the multi-compound combination strategy and distinguished from short-acting amylin / GLP-1 combination predecessors by the long-acting pharmacokinetic profile of both component compounds.
Selected peer-reviewed and primary-source citations used to inform this educational overview. Inclusion does not imply endorsement of any non-research use of DRJAYS Cagri-Sema™ 5MG (Cagrilintide + Semaglutide Blend).
Explore the Dr Jays Peptide Encyclopedia and research library for deeper background, mechanisms, and stack guidance.
